Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 200

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease

De LEON, M. J., MOSCONI, L., BLENNOW, K., DeSANTI, S., ZINKOWSKI, R., MEHTA, P. D., PRATICO, D., TSUI, W., LOUIS, L. A. SAINT, SOBANSKA, L., BRYS, M., LI, Y., RICH, K., RINNE, J., RUSINEK, H.·2007·Annals of the New York Academy of Sciences

Abstract

Abstract: It is widely believed that the path to early and effective treatment for Alzheimer's disease (AD) requires the development of early diagnostic markers that are both sensitive and specific. To this aim, using longitudinal study designs, we and others have examined magnetic resonance imaging (MRI), 2‐fluoro‐2‐deoxy‐d‐glucose‐positron emission tomography (FDG/PET), and cerebrospinal fluid (CSF) biomarkers in cognitively normal elderly (NL) subjects and in patients with mild cognitive impairment (MCI). Such investigations have led to the often replicated findings that structural evidence of hippocampal atrophy as determined by MRI, as well as metabolic evidence from FDG‐PET scan of hippocampal damage, predicts the conversion from MCI to AD. In this article we present a growing body of evidence of even earlier diagnosis. Brain pathology can be detected in NL subjects and used to predict future transition to MCI. This prediction is enabled by examinations revealing reduced glucose metabolism in the hippocampal formation (hippocampus and entorhinal cortex [EC]) as well as by the rate of medial temporal lobe atrophy as determined by MRI. However, neither regional atrophy nor glucose metabolism reductions are specific for AD. These measures provide secondary not primary evidence for AD. Consequently, we will also summarize recent efforts to improve the diagnostic specificity by combining imaging with CSF biomarkers and most recently by evaluating amyloid imaging using PET. We conclude that the combined use of conventional imaging, that is MRI or FDG‐PET, with selected CSF biomarkers incrementally contributes to the early and specific diagnosis of AD. Moreover, selected combinations of imaging and CSF biomarkers measures are of importance in monitoring the course of AD and thus relevant to evaluating clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1196/annals.1379.012

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 38 references

Cited by

See all 200

Metadata

Authors
De LEON, M. J., MOSCONI, L., BLENNOW, K., DeSANTI, S., ZINKOWSKI, R., MEHTA, P. D., PRATICO, D., TSUI, W., LOUIS, L. A. S., SOBANSKA, L., BRYS, M., LI, Y., RICH, K., RINNE, J., & RUSINEK, H.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2007-02
Volume
1097
Issue
1
Pages
114-145
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W2045693977
Cited by
200
References
38
FWCI
13.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease. https://app.cochat.ai/papers/10.1196/annals.1379.012
The paper
De LEON, M. J., MOSCONI, L., BLENNOW, K., DeSANTI, S., ZINKOWSKI, R., MEHTA, P. D., PRATICO, D., TSUI, W., LOUIS, L. A. S., SOBANSKA, L., BRYS, M., LI, Y., RICH, K., RINNE, J., & RUSINEK, H. (2007). Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1379.012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.